Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JWP24
- Development stage
- Unknown
- Lead developer
- University of North Carolina at Chapel Hill
- Modality
- Peptides
01
Overview
JWP24: sourced facts only. name: "we developed JWP24, the first cell-permeable peptide inhibitor of MAGE-A4." [PMID:40937506]; target: "we developed JWP24, the first cell-permeable peptide inhibitor of MAGE-A4." [PMID:40937506]; developer: "Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States." [PMID:40937506]; modality: "we developed JWP24, the first cell-permeable peptide inhibitor of MAGE-A4." [PMID:40937506]
02
Targets
MAGEA4 (Melanoma-associated antigen A4)
Beyond the preview
Go deeper on JWP24.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JWP24.